Literature DB >> 16338246

Schizophrenia and increased risks of cardiovascular disease.

Charles H Hennekens1, Alissa R Hennekens, Danielle Hollar, Daniel E Casey.   

Abstract

OBJECTIVE: The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia. DATA SOURCES: We reviewed published articles on causes of mortality in the general population as well as among patients with schizophrenia. STUDY SELECTION: We selected articles which published total and cause-specific mortality rates. DATA EXTRACTION: We reviewed the causes of mortality and their risk factors. DATA SYNTHESIS: The average life expectancy of the general population is 76 years (72 years in men, 80 years in women), whereas the corresponding figure is 61 years (57 years in men, 65 years in women) among patients with schizophrenia. Thus, patients with schizophrenia have approximately a 20% reduced life expectancy compared with the general population. Although patients with schizophrenia are 10 to 20 times more likely than the general population to commit suicide, more than two thirds of patients with schizophrenia, compared with approximately one-half in the general population, die of coronary heart disease (CHD). The chief risk factors for this excess risk of death are cigarette smoking, obesity leading to dyslipidemia, insulin resistance and diabetes, and hypertension.
CONCLUSIONS: The chief cause of excess premature mortality among patients with schizophrenia is CHD, caused mainly by their adverse risk factor profile. Because patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant with their regimens, the choice of antipsychotic drug regimens that do not further adversely affect their risk factor for CHD is a major clinical and public health challenge among patients with schizophrenia.

Entities:  

Mesh:

Year:  2005        PMID: 16338246     DOI: 10.1016/j.ahj.2005.02.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  278 in total

1.  Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Vinod H Srihari; Cenk Tek
Journal:  Psychosomatics       Date:  2012-06-02       Impact factor: 2.386

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status.

Authors:  Philip D Harvey; Martin Strassnig
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

4.  Accelerated white matter aging in schizophrenia: role of white matter blood perfusion.

Authors:  Susan Wright; Peter Kochunov; Joshua Chiappelli; Robert McMahon; Florian Muellerklein; S Andrea Wijtenburg; Michael G White; Laura M Rowland; L Elliot Hong
Journal:  Neurobiol Aging       Date:  2014-02-28       Impact factor: 4.673

Review 5.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders.

Authors:  Tyler Grove; Stephan Taylor; Gregory Dalack; Vicki Ellingrod
Journal:  Schizophr Res       Date:  2015-02-23       Impact factor: 4.939

7.  Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.

Authors:  Thomas J Vassas; Kyle J Burghardt; Vicki L Ellingrod
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

8.  Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia.

Authors:  Kristen M Ward; Larisa Yeoman; Cora McHugh; A Zarina Kraal; Stephanie A Flowers; Amy E Rothberg; Alla Karnovsky; Arun K Das; Vicki L Ellingrod; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2018-06       Impact factor: 4.705

9.  Metabolic Effects of Antidepressant Treatment.

Authors:  Özlem Olguner Eker; Saliha Özsoy; Baki Eker; Hatice Doğan
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

10.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.